[ad_1] –Clinically meaningful and statistically significant results demonstrated for primary endpoint and key secondary endpoints for the 12-week induction period– –Etrasimod was well-tolerated and its safety profile was consistent with…
Tag: Everest
Everest Medicines Announces Acceptance of Nefecon® New Drug Applications for the Treatment of Primary IgA Nephropathy in Adult Patients in South Korea
[ad_1] SHANGHAI, Nov. 29, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines,…
Everest Medicines Announces China NMPA’s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients
[ad_1] –Nefecon® is the first approved medicine with an IgAN indication in China— –The approval marks a new era of IgAN treatment for Chinese patients– SHANGHAI, Nov. 23, 2023 /PRNewswire/…
EvoluteIQ Recognized as a Star Performer and a Major Contender for Second Consecutive Year on Everest Group’s Process Orchestration Products PEAK Matrix® Assessment 2023
[ad_1] STOCKHOLM, Nov. 9, 2023 /PRNewswire/ — EvoluteIQ, a leading intelligent business automation platform provider, has been positioned as a Major Contender for the second consecutive year and a Star…
Everest Medicines’ Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis | BioSpace
[ad_1] SHANGHAI, Oct. 15, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug…
Everest Medicines’ Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis
[ad_1] SHANGHAI, Oct. 15, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug…
Everest Medicines Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients
[ad_1] SHANGHAI, Sept. 27, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines,…
Everest unveils business travel accident coverage – Business Insurance
[ad_1] Everest Insurance, the insurance division of Everest Group Ltd., Monday said it has launched Everest Business Travel Accident Insurance within its Accident and Health portfolio. The coverage combines insurance…
NTT DATA Named a Leader in Everest Group’s Blockchain PEAK Matrix® 2023 Report
[ad_1] September 19, 2023 NTT DATA Group Corporation TOKYO – September 19, 2023 – NTT DATA, a digital business and IT services leader, today announced that it has been named…
Everest Medicines Announces Interim Results for First Half of 2023
[ad_1] SHANGHAI, Aug. 23, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines,…